Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A comprehensive study found that 85% of pediatric chemotherapy errors reached patients, with most common mistakes involving improper dosing and timing. The antimetabolite class of chemotherapeutic agents was most frequently associated with errors, highlighting the need for targeted medication administration safeguards.
Scientists developed a new mouse model that closely mimics human cancers, enabling researchers to identify cancer-causing genes and improve laboratory drug testing. The model's genetic instability was found to be similar to that in human tumors, suggesting its potential for guiding gene discovery.
A colon cancer researcher outlines the benefits of aspirin in preventing colon cancer in high-risk individuals. Dr. Sanford Markowitz' editorial provides a roadmap for how medical science should employ aspirin and new aspirin-like drugs to decrease the risk of developing colon cancer.
New guidelines provide a rational treatment approach for managing skin reactions caused by Epidermal Growth Factor Receptor Inhibitors (EGFRIs), which are used to treat various types of cancer. The recommended treatment involves using moisturizers, protecting against sunlight, and targeted medications to manage the severity of the rash.
A subset of endometrial cancers has been found to have previously unrecognized alterations in the FGFR2 gene, resulting in uncontrolled cell division. This discovery could accelerate the development of new treatments for endometrial cancer by targeting drugs already in clinical trials.
Researchers have developed a nanocomposite particle that can target and destroy melanoma cancer cells using laser irradiation. The technology utilizes selectively absorbing metallic clusters to enhance light absorption within labeled cells, causing damage without affecting surrounding tissue.
Two UI studies show that the NSAID celecoxib has potent anticancer activity, killing head and neck cancer cells in the S phase of the cell cycle. This finding suggests that combining celecoxib with chemotherapies may provide better tumor control than radiation alone.
UC patients report a heavy psychological toll, with 82% experiencing increased stress and 62% feeling depressed. Nearly four out of five patients worry about long-term health effects, such as colon cancer or surgery. Non-compliance with medication is also a challenge, affecting up to half of patients.
Reolysin works synergistically with standard anti-cancer drugs, providing stronger responses than either agent alone. It also primes patients' immune systems against their particular cancer, leading to additional cancer cell killing and long-term remissions.
A report by European Society for Medical Oncology reveals stark inequalities in access to cancer treatment globally. Key findings include that Austria, France, and the US have high uptake of new cancer drugs, while countries like New Zealand, Poland, and South Africa have low uptake.
Researchers found that combining a diabetes drug with platinum-based chemotherapy boosted its potency in various cancer cell lines and mouse tumors. The combination halted or shrunk tumors up to three times more effectively than either drug alone.
A new study finds that the re-engineered Gleevec variant WBZ-7 is effective against both drug-resistant and nonresistant gastrointestinal cancer cells. The wrapping prototype seals out water molecules from a critical area, preventing resistance to the drug, and demonstrates promising results in laboratory studies.
Researchers found that chronic myeloid leukemia stem cells have a high frequency of BCR-ABL gene mutations, even in the absence of imatinib, which could lead to drug resistance. This genetic instability may contribute to relapses and disease progression.
A promising anti-inflammatory drug failed to improve symptoms of moderate to severe chronic obstructive pulmonary disease (COPD) in a large trial. The study suggests that other mediators may be necessary to cause COPD, and raises concerns about the safety of the drug.
Researchers from Duke University found that generic biologics are unlikely to be significantly cheaper than brand-name versions due to higher manufacturing and marketing costs. The unique characteristics of biologics make them harder to replicate, resulting in lower price competition.
Researchers discovered a new way lung tumors become resistant to targeted therapy drugs like Iressa and Tarceva, involving the activation of an oncogene that bypasses blocked growth signal. A potential new treatment strategy using combination therapy against both protein targets is suggested for patients with resistant tumors.
The Phase III efficacy clinical trial showed statistically significant improvement on the primary efficacy endpoint at 30 minutes compared to placebo, indicating a greater reduction in pain. Patients treated with BEMA Fentanyl also demonstrated well-tolerated treatment with no reported drug-related changes to the oral mucosa.
The study found that lung cancer cells can become resistant to novel targeted agents by undergoing a miniscule molecular change in the EGFR protein. Researchers developed compounds to overcome resistance with innovative combinations of medications, which showed promise in preventing further resistance.
A new study suggests that targeting the survival protein Mcl1 may be an effective way to treat leukemia, particularly when combined with existing drugs like rituximab. The research found that knocking out Mcl1 can cause cancer cells to die, and combining it with rituximab killed significantly more leukemia cells than the drug alone.
Researchers found that the androgen receptor plays a key role in bladder cancer development, which explains why it affects men more than women. The discovery opens doors to new treatment options and may help doctors predict tumor recurrence.
Researchers at MGH Cancer Center have discovered a molecular pathway underlying sensitivity to cisplatin in triple-negative breast cancers. The study found that p63 and p73 expression levels can predict cisplatin therapy effectiveness, leading to the design of a clinical trial for patients with advanced triple-negative breast cancer.
Triple-negative breast cancer cells are sensitive to cisplatin due to increased expression of delta-Np63 and TAp73 proteins. Cisplatin releases TAp73 from delta-Np63, leading to cell death. This study suggests using cisplatin as an early treatment option for individuals with triple-negative breast cancer.
Researchers have found that the novel targeted therapy NPI-0052 effectively treats acute leukemia in animal models by preventing cancer cells from being purged of damaged proteins. This approach has shown greater efficacy than its predecessor bortezomib when combined with other agents.
Researchers have identified gene expression signatures that can predict how individuals will respond to certain breast cancer drugs. These biomarkers could aid in tailoring treatments for women and identifying similar biomarkers for other types of cancer. A 'systems' approach suggests prioritizing experimental medicines for specific ca...
A study found that nearly a third of cancer patients take at least one medication that can cause serious harm or interact with other medications, including anticancer treatments. The most common interactions involve warfarin and anticonvulsants, posing significant risks to patients with brain tumors.
A novel cell culture technique could lead to the discovery of new drugs for preventing DCIS recurrence or progression. Breast cancer cells expressing a shortened form of the HER2 gene can be treated with lapatinib, but are resistant to trastuzumab.
The AACR-FDA-NCI Cancer Biomarkers Collaborative aims to integrate predictive biomarkers into clinical trials, addressing the translation of cancer knowledge into medical practice. The collaborative will develop guidelines for biomarker validation, informing policies as part of the FDA's Critical Path Initiative.
A phase III trial of 1,298 patients found that a combination of cetuximab and irinotecan increased progression-free survival over irinotecan alone. The treatment also showed a higher tumor response rate.
Researchers at Virginia Commonwealth University Massey Cancer Center have induced cell death in leukemia cells using a combination of bortezomib and romidepsin or belinostat. The findings suggest potentiated lethality and additive effects in human CLL cells.
A new protein-targeted drug, MCP110, has been found to have a synergistic effect when combined with current chemotherapy drugs like taxanes and vinca-alkaloid compounds. This combination improves the efficacy of systemic treatment for human lung and colon cancer cells.
Researchers discovered that an investigational cancer drug selectively kills cancer cells due to its affinity for a modified version of heat shock protein 90. The modification, called acetylation, allows the drug to target and block the activity of this protein, promoting cell survival.
Researchers found that patients who received Gleevec after surgery were significantly less likely to have cancer recurrence compared to those who didn't receive it. The study showed a 97% survival rate for patients on Gleevec, with only mild side effects reported.
The American Association for Cancer Research will present the AACR Distinguished Service Award and the AACR Public Service Award to Dr. Andrew C. von Eschenbach, Dr. Harold P. Freeman, and Dr. LaSalle D. Leffall, Jr., recognizing their outstanding contributions to leadership, education, and advocacy in cancer research. The awards will ...
A Princeton University-led research team has developed nanoparticles that can deliver medicine deep into the lungs or infiltrate cancer cells while leaving normal ones alone. The particles are too large to pass through normal cells but can target rapidly growing solid tumors and remain in the lungs, maximizing the effectiveness of inha...
Researchers at Jefferson University identified a protein called Akt1 that plays a crucial role in helping breast cancer cells spread. The finding could lead to the development of new drugs targeting this protein, potentially slowing or stopping the growth and progression of breast cancer.
Scientists have found a new approach to treating human cancers by understanding how a plant hormone, auxin, interacts with its receptor, TIR1. This discovery may lead to the development of new cancer drugs by targeting ubiquitin ligases, which are involved in various human diseases.
A new study from UCSD reveals that California's tobacco control program has led to a significant increase in smoking cessation rates, especially among young adults. Cessation rates have risen by 50% among those aged 20-34, while daily cigarette consumption has declined, particularly among older smokers.
Scientists have identified a natural mechanism by which tumors and viruses evade the immune response, leading to the development of new cancer therapies. By inhibiting an enzyme called IDO, researchers hope to restore the immune system's ability to target cancer cells. Early clinical trials are underway to test this approach.
Researchers at the University of Guadalajara have developed a natural drug carrier derived from tequila that shows promise in targeting colon diseases. The microspheres, made from fructans, can protect drugs from stomach acid and improve their effectiveness.
Research at St. Jude Children's Research Hospital shows that leukemic cells receive a protective niche from bone marrow mesenchymal cells, which release the amino acid asparagine to help them survive treatment with asparaginase. This finding suggests new strategies for enhancing anti-leukemic drugs and reducing leukemia recurrence rates.
A study on rheumatoid arthritis found that flexible use of drugs with close patient follow-up can effectively control the disease. Additionally, a trial on men with prostate cancer showed that an osteoporosis drug strengthens bones and reduces bone loss.
Researchers at the University at Buffalo have developed a novel drug delivery system using nanocrystals of hydrophobic drugs, which can target tumors with comparable efficacy to conventional surfactant-based systems. The system eliminates the need for separate carriers, reducing toxicity and improving drug penetration.
A study from UNC School of Medicine suggests that improving healthcare access is key to reducing disparities in prostate cancer among black men. The lack of regular healthcare and trust in physicians hindered their ability to receive preventative care, leading to higher death rates.
Researchers at the University of Pennsylvania have discovered a way to pre-screen cancer patients for blood cancer drugs by testing for p53, a tumor-suppressor protein. This test may help identify patients who are most likely to respond to treatment and avoid harmful side effects.
A study published in Cell Press found that the p53 gene, known for preventing cancer, also regulates the suntan response. The researchers discovered that p53 activates the tanning machinery, protecting against sunburns. The findings may lead to new products that produce a tan safely without UV radiation exposure.
Researchers found that changes in breast density over time can predict a woman's risk of breast cancer, with higher densities linked to greater risks. Meanwhile, targeting prostate-specific proteins may lead to effective treatments for prostate cancer and other diseases, leaving non-prostate cells unharmed.
Researchers at the University of Missouri-Columbia have found that a plant extract can be used to stabilize gold nanoparticles, making them nontoxic and stable enough for injection or oral administration. This breakthrough has the potential to revolutionize cancer detection and treatment using nanomedicine.
A recent USC-led study suggests that long-term recreational physical activity plays a protective role against invasive and in situ breast cancer. Women exercising for five or more hours per week experienced a greater decrease in risk of breast cancer compared to less active women.
Researchers at Georgetown University Medical Center have isolated a protein, caveolin-1, that enhances cell death in response to Taxol chemotherapy in breast cancer cells. The protein needs to be phosphorylated to work, and its expression level can vary depending on the type of breast cancer.
A new class of targeted cancer drugs, pertuzumab, shows promise in slowing the progression of recurrent prostate cancer. The study found that prolonged median survival time was achieved by 16.4 months with the drug compared to 10.7 months in a historical control group.
A phase III clinical trial found that the first antisense drug, oblimersen, improved response rates in CLL patients who remained sensitive to chemotherapy drug fludarabine. The study showed a four-fold increase in 'CR/nPR' in these patients compared to those no longer responding to fludarabine.
A new study reveals that breast cancer patients taking tamoxifen who switch to an aromatase inhibitor within three years experience significant improvements in survival rates. The treatment demonstrates a clear survival benefit without an increased risk of death from other causes.
A novel drug sequence combining tamoxifen and exemestane has been shown to improve breast cancer survival rates in postmenopausal women by 17%, according to a new study. The treatment sequence was found to be safe and well-tolerated, offering hope for improved treatment options for patients worldwide.
Researchers at Dana-Farber Cancer Institute and Broad Institute develop a practical method for screening tumors for cancer-related gene abnormalities, paving the way for personalized medicine. The technique uses high-throughput genotyping to detect important mutations in oncogenes with high accuracy and sensitivity.
Researchers create an array of magnetic-field sensors to detect tiny magnetic spheres, which can bind with cell receptors. This technology enables rapid evaluation of potential antiviral drugs and high-precision detection of cancer biomarkers.
Researchers at UT Southwestern Medical Center discovered a toxin from a sea creature that blocks cancer cell division while leaving healthy cells unaffected. A synthetic form of the toxin, diazonamide, showed promise in pre-clinical trials without harmful side effects.
A large British study indicates that individuals with severe mental illnesses are significantly more likely to die from coronary heart disease and stroke than those without mental illnesses. The use of antipsychotic medication also contributes to the increased risk of death from cardiovascular disease.
A survey of 1,142 patients with chronic moderate to severe plaque psoriasis found that nearly 40% are not receiving treatment. The study also showed that those with severe psoriasis are more likely to have a lower household income.
AkaRx has licensed the tetrac patents for treating thyroid cancer, developing AKR-201 to suppress TSH production. The drug aims to reduce side effects of hyperthyroidism in patients with thyroid cancer
A new study has discovered a potential link between an approved obesity drug and cancer treatment. Researchers found that the drug Orlistat can block fatty acid synthase, an enzyme crucial for tumor cell growth, promoting cell death instead.